Anavex Life Sciences Corp (NASDAQ:AVXL)

5.81
Delayed Data
As of Jan 15
 -0.11 / -1.86%
Today’s Change
2.20
Today|||52-Week Range
7.69
+7.59%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$389.7M

Company Description

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Contact Information

Anavex Life Sciences Corp.
51 West 52nd Street
New York New York 10019-6163
P:(800) 689-3939
Investor Relations:

Employees

Shareholders

Other institutional8.24%
Individual stakeholders3.84%
Mutual fund holders10.96%

Top Executives

Christopher U. MisslingChairman, President, CEO & Secretary
Stephan ToutainChief Operating Officer
Sandra BoenischPrincipal Financial Officer & Treasurer
Walter E. KaufmannChief Medical Officer
Daniel KlamerVP-Business Development & Scientific Strategy